Alx oncology to host investor call and webcast to share topline data results from aspen-06 phase 2 clinical trial of evorpacept for the treatment of advanced her2-positive gastric cancer

South san francisco, calif., july 31, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or the “company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, announced that the company will host an investor conference call and webcast today at 4:30 pm edt to share topline data results from the phase 2 aspen-06 clinical trial evaluating evorpacept for the treatment of advanced her2-positive gastric cancer.
ALXO Ratings Summary
ALXO Quant Ranking